e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension
David Macias, Stephen Moore, Alexi Crosby, Mark Southwood, Xinlin Du, Huiling Tan, Shanhai Xie, Arlette Vassallo, Alexander J.T. Wood, Eli M. Wallace, Andrew S. Cowburn
Source:
Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019
Journal Issue:
March
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
David Macias, Stephen Moore, Alexi Crosby, Mark Southwood, Xinlin Du, Huiling Tan, Shanhai Xie, Arlette Vassallo, Alexander J.T. Wood, Eli M. Wallace, Andrew S. Cowburn. Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension. Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Novel therapeutic perspectives in pulmonary arterial hypertension
Source: Eur Respir J 2003; 22: 193-194
Year: 2003
Survivin inhibition as a potential target for pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
The role of combination therapy in managing pulmonary arterial hypertension
Source: Eur Respir Rev 2014; 23: 469-475
Year: 2014
Targeting BMPR-II in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches
Year: 2016
Leptin signalling system as a target for pulmonary arterial hypertension therapy
Source: Eur Respir J 2015; 45: 1066-1080
Year: 2015
Novel insights into the pathogenesis of pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pulmonary vascular diseases
Year: 2020
The pathophysiological role of novel pulmonary arterial hypertension gene
SOX17
Source: Eur Respir J, 58 (3) 2004172; 10.1183/13993003.04172-2020
Year: 2021
Optimal management of severe pulmonary arterial hypertension
Source: Eur Respir Rev 2011; 20: 254-261
Year: 2011
Fibrocytes: potential new therapeutic targets for pulmonary hypertension?
Source: Eur Respir J 2010; 36: 1232-1235
Year: 2010
Novel biomarkers in idiopathic pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 408-417
Year: 2016
Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension
Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020
Year: 2020
Identification of treatment goals in paediatric pulmonary arterial hypertension
Source: Eur Respir J 2014; 44: 1616-1626
Year: 2014
The future of treatment for pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
The future of treatment for pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012
The future of treatment for pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
The future of treatment for pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
Novel techniques for advancing our understanding of pulmonary arterial hypertension
Source: Eur Respir J, 53 (5) 1900556; 10.1183/13993003.00556-2019
Year: 2019
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept